109 related articles for article (PubMed ID: 30914029)
1. Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
Wright JW; Church KJ; Harding JW
Curr Cancer Drug Targets; 2019; 19(10):782-795. PubMed ID: 30914029
[TBL] [Abstract][Full Text] [Related]
2. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
3. Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
Church KJ; Vanderwerff BR; Riggers RR; Mateo-Victoriano B; Fagnan M; Harris PH; LeValley JC; Harding JW
Anticancer Drugs; 2018 Apr; 29(4):295-306. PubMed ID: 29389804
[TBL] [Abstract][Full Text] [Related]
4. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
Yamamoto BJ; Elias PD; Masino JA; Hudson BD; McCoy AT; Anderson ZJ; Varnum MD; Sardinia MF; Wright JW; Harding JW
J Pharmacol Exp Ther; 2010 Apr; 333(1):161-73. PubMed ID: 20086056
[TBL] [Abstract][Full Text] [Related]
5. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
6. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity.
Kawas LH; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2011 Nov; 339(2):509-18. PubMed ID: 21859930
[TBL] [Abstract][Full Text] [Related]
7. Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
Sugie S; Mukai S; Yamasaki K; Kamibeppu T; Tsukino H; Kamoto T
Hum Cell; 2016 Jan; 29(1):22-9. PubMed ID: 26250899
[TBL] [Abstract][Full Text] [Related]
8. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.
Kawas LH; McCoy AT; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2012 Mar; 340(3):539-48. PubMed ID: 22129598
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
[TBL] [Abstract][Full Text] [Related]
10. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.
Nan L; Qin T; Xiao Y; Qian W; Li J; Wang Z; Ma J; Ma Q; Wu Z
Cell Transplant; 2019; 28(9-10):1289-1298. PubMed ID: 31161784
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor and macrophage-stimulating protein are upregulated during excisional wound repair in rats.
Cowin AJ; Kallincos N; Hatzirodos N; Robertson JG; Pickering KJ; Couper J; Belford DA
Cell Tissue Res; 2001 Nov; 306(2):239-50. PubMed ID: 11702235
[TBL] [Abstract][Full Text] [Related]
14. An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity.
Michieli P; Cavassa S; Basilico C; De Luca A; Mazzone M; Asti C; Chiusaroli R; Guglielmi M; Bossù P; Colotta F; Caselli G; Comoglio PM
Nat Biotechnol; 2002 May; 20(5):488-95. PubMed ID: 11981563
[TBL] [Abstract][Full Text] [Related]
15. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
16. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
[TBL] [Abstract][Full Text] [Related]
19. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
